Introduction {#s1}
============

Long-acting reversible contraception (LARC) methods, including intrauterine contraception (IUC), are intrinsically highly effective and their effectiveness does not depend on user compliance ([@DMT022C54]; [@DMT022C57]). Thus, with more widespread use of LARC methods, the rate of unintended pregnancy could be reduced.

Women who have the best knowledge of IUC are more likely to use it personally. In a survey of female Fellows of the American College of Obstetricians and Gynecologists, the prevalence of personal IUC use was \>20-fold higher than among women in the general population ([@DMT022C4]). Similarly, a high prevalence of IUC use has been reported among midwives ([@DMT022C18]). Our anecdotal observations also suggest a similar high prevalence of IUC use among various women\'s healthcare professionals (HCP), including physicians, nurse practitioners and nurse-midwives.

The Contraceptive CHOICE Project showed that when women requesting contraception were given unbiased information on LARC methods and then given a free choice of any contraceptive method provided free of charge, the majority (56%) chose IUC ([@DMT022C44]; [@DMT022C42]).

Fear of pain during insertion, however, might prevent some women from choosing IUC ([@DMT022C26]; [@DMT022C1]) and HCPs\' fears of painful and/or difficult placements may lead them to recommend or counsel women on other, less effective contraceptive methods ([@DMT022C23]).

Women\'s perception of pain is multifactorial and likely to be influenced by cultural differences and personal experiences; insertion-related pain is therefore difficult to predict. Nevertheless, factors associated with greater pain include nulliparity, not currently breastfeeding and longer time since last pregnancy; of these factors, nulliparity is the strongest predictor of pain ([@DMT022C11], [@DMT022C12]; [@DMT022C33]; [@DMT022C26]). The proportion of sexually active women of reproductive age who are nulliparous is increasing, with women delaying childbirth and having fewer children or choosing to remain childless ([@DMT022C2]). The proportion of Caesarean section births has also increased ([@DMT022C7]; [@DMT022C55]; [@DMT022C8]; [@DMT022C49]), and women who have only ever had a Caesarean section are often viewed as nulliparous with respect to IUC placement.

Anticipated pain is often greater than the actual pain experienced ([@DMT022C39]), and the majority of nulliparous women experience no more than moderate pain during IUC insertion ([@DMT022C50]; [@DMT022C9]; [@DMT022C35]). In a prospective study in 117 nulliparous women, the majority (62%) reported that the pain associated with the procedure was similar in intensity to that of menstruation ([@DMT022C9]), although for some women, menstrual pain can be severe enough to require pain relief. In a non-interventional study in 224 nulliparous women, 9% reported no pain and 72% reported moderate pain during insertion of a levonorgestrel intrauterine system (LNG-IUS) ([@DMT022C35]).

However, among nulliparous women there is a subset (about 17%) for whom the insertion of IUC is associated with severe pain ([@DMT022C35]) and among parous women (mean of two prior births; *n* = 46) ∼11% report severe pain ([@DMT022C23]). These women need effective pain relief.

The aim of this review is to critically evaluate the evidence for various pain management strategies and formulate evidence-based recommendations. In the absence of conclusive evidence, a group consensus is presented. Data gaps and areas for further research are also discussed. It is not within the scope of this article to review the evidence for the management of other side effects, such as vasovagal reactions.

Methods {#s2}
=======

A literature search was undertaken using PubMed. Relevant articles on management of pain associated with IUC insertion, published in English between 1980 and November 2012, were identified using the following search terms: 'intrauterine contraception', 'insertion' and 'pain'. We reviewed and included primary RCTs; further relevant supporting articles were identified and included as appropriate. Relevant references from the bibliographies of included articles were also reviewed and included when appropriate.

Seventeen studies were identified and included: 12 RCTs and one non-randomized study of pre-insertion oral analgesia, cervical priming and local anaesthesia; one systematic review and one RCT on post-insertion analgesia and two non-randomized studies on non-pharmacological interventions.

Pain management strategies: critical review of the evidence and expert consensus {#s3}
================================================================================

No comprehensive strategy has been developed for managing pain associated with the insertion of IUC and no standard has been established. Current pharmacological strategies include: pre-insertion therapy (oral analgesia, cervical ripening/priming and local anaesthesia); therapy given during the procedure (local anaesthesia administered reactively) and post-procedure therapy (non-steroidal anti-inflammatory drugs \[NSAIDs\] and opioid analgesia). Non-pharmacological pain management strategies include psychological preparation and counselling before insertion and 'verbal anaesthesia' and distraction during the procedure. The evidence for each of these strategies is reviewed below.

Pre-insertion pharmacological therapy {#s3a}
-------------------------------------

### Oral analgesia {#s3a1}

Prophylactic administration of ibuprofen or another NSAID is widespread despite a lack of supporting evidence, possibly because providers and/or women believe that, as an effective analgesic, it might reduce pain caused by IUC insertion.

Three RCTs have evaluated the prophylactic use of oral analgesia versus placebo for reducing pain associated with IUC insertion ([@DMT022C26]; [@DMT022C13]; [@DMT022C31]) (Table [I](#DMT022TB1){ref-type="table"}). Table IStudies of pre- and post-placement pharmacological interventions for the reduction of pain associated with IUC insertion.Reference*n*PopulationInterventionsMethod of evaluation of pain^a^Significance of pain reduction effectLevel of evidence^b^Pre-insertion oral analgesia[@DMT022C26]2019Nulliparous and parous400 mg ibuprofen versus placeboOverall pain measured on 0--10 VASNot significant (median score 1.0 in both treatment groups)2[@DMT022C13]81Mainly parous (96%)800 mg ibuprofen versus placeboMeasured at different time points on 0--10 VASNot significant (mean score during actual insertion 3.69 versus 3.34, *P* = 0.91)2[@DMT022C31]10350 mg tramadol versus 550 mg naproxen sodium versus placeboOverall pain measured on 0--10 VASSignificant reduction in mean pain score with tramadol versus naproxen sodium (2.31 versus 2.94, *P* = 0.003) and with naproxen sodium versus placebo (2.94 versus 4.88, *P* = 0.001)*2*Pre-insertion cervical priming[@DMT022C43]80Nulliparous400 µg misoprostol (sublingual) versus placeboOverall pain measured on 0--10 VASNot significant (median score 7.0 versus 6.5, *P* = 0.20)2[@DMT022C23]89Mainly parous (94%)400 µg misoprostol (sublingual) versus placeboOverall pain measured as 'none', 'mild', 'moderate' or 'severe'Not significant (no more than mild pain reported in 37 and 35% of subjects in the misoprostol and placebo groups, respectively)2[@DMT022C17]40Nulliparous400 µg misoprostol (buccally) versus placeboMeasured at different time points on 0--100 VASNot significant (mean score during actual insertion 65 versus 55, *P* = 0.83)2[@DMT022C15]199Nulliparous and parous400 µg misoprostol (vaginally) versus placeboOverall pain measured on 0--100 VASNot significant (mean score 46 versus 40, *P* = 0.14)2[@DMT022C51]108Nulliparous400 µg misoprostol (vaginally or buccally) versus placeboMeasured at different time points on 0--100 VASNot significant (mean score during actual insertion 58.4 versus 56.9, *P* = 0.74)2Pre-insertion local anaesthesia[@DMT022C41]102Nulliparous and parous2% lignocaine gel (intracervically) versus placebo gel versus no treatmentOverall pain measured on 1--7 VASSignificant reduction in pain (distribution of subjects with pain scores of 1--2, 3--4 and 5--7 differed significantly between treatment groups, *P* \< 0.025)2 (flawed study design)^c^[@DMT022C34]197Nulliparous and parous2% lignocaine gel versus placebo gelMeasured at different time points on 0--100 VASNot significant (mean score during actual insertion 51.0 versus 50.9, *P* = 0.98)2[@DMT022C36]199Nulliparous and parous2% lignocaine gel versus placebo gelMeasured at different time points on 0--10 VASNot significant (median score during actual insertion 5 versus 6, *P* = 0.16)2[@DMT022C38]50Nulliparous and parous1% lignocaine paracervical block versus no anaesthesiaMeasured at different time points on 0--100 VASNot significant (median score during actual insertion 24.0 versus 62.0, *P* = 0.09)2Post-insertion pharmacological therapy[@DMT022C21]Systematic reviewNSAID versus placeboSignificant reduction in pain when used to reactively treat post-insertion pain. No significant effect when given prophylactically1[@DMT022C19]59Mainly nulliparousMeptazinol versus placeboPain relief rated as 'excellent', 'good', 'fair', 'poor' or 'inadequate' at 7 days after insertionNot significant (pain relief rated as 'good' or 'excellent' in 67 and 69% of subjects, in the meptazinol and placebo groups, respectively)2[^1][^2][^3][^4]

In the first RCT, 2019 nulliparous or parous 'first-time' users of the copper intrauterine device (IUD) received either 400 mg ibuprofen or placebo at least 45 min before the procedure ([@DMT022C26]). Ibuprofen had no significant effect on patient-reported pain compared with placebo. Certain subgroups (e.g. nulliparous women) experienced more pain than others, but ibuprofen had no clinically relevant impact on the level of pain compared with placebo.

In the second RCT, 81 women received either 800 mg ibuprofen or placebo 45 min before the insertion of an LNG-IUS ([@DMT022C13]). Prophylactic use of ibuprofen had no significant impact on mean scores for anticipated pain, pain associated with tenaculum application or pain associated with the actual insertion.

In the third RCT, 103 women received 50 mg tramadol (*n* = 35), 550 mg naproxen sodium (*n* = 34) or placebo (*n* = 34) 1 h before IUC insertion ([@DMT022C31]). Women reported the pain they experienced on insertion using a 0--10 visual analogue scale (VAS). Tramadol was associated with a significant reduction in pain compared with naproxen sodium (*P* = 0.003), and naproxen sodium was associated with a significant reduction in pain compared with placebo (*P* = 0.001).

A further UK-based, non-randomized, single-centre study of 109 nulliparous and parous women concluded that the pain scores reported by women who took pre-insertion analgesia (mainly ibuprofen) were not significantly different to the pain scores reported by those who did not take any pre-insertion analgesia ([@DMT022C39]).

#### Study limitations {#s3a1a}

The analgesia regimens evaluated in these studies were not optimized for IUC insertion, e.g. type of analgesia, dose and timing before the procedure. Instead, the regimens used were extrapolated from other gynaecological settings (abortion and hysteroscopy).

#### Group consensus {#s3a1b}

There is currently no evidence to recommend routine prophylactic use of ibuprofen; there is no evidence that it reduces insertion-related pain.

Data from one small study suggest that the prophylactic use of the atypical opioid analgesic tramadol, or the NSAID naproxen sodium, may reduce pain on IUC insertion. However, larger follow-up studies are required to confirm these preliminary findings.

### Cervical priming {#s3a2}

In an online US-based survey of 1905 providers who regularly insert IUC in nulliparous women, 50% reported using misoprostol and 40% of misoprostol users reported that they routinely used it in all nulliparous women ([@DMT022C56]). However, wide variation was reported in the dose used, as well as in the route and timing of administration. This reflects the current lack of studies defining the optimal misoprostol regimen and the lack of data on the 'real-world' usefulness of cervical priming in this setting.

The impact of cervical priming with misoprostol on pain associated with IUC insertion has been evaluated in five placebo-controlled RCTs ([@DMT022C43]; [@DMT022C23]; [@DMT022C15]; [@DMT022C17]; [@DMT022C51]) (Table [I](#DMT022TB1){ref-type="table"}).

In the first RCT, 80 nulliparous women received either 400 µg sublingual misoprostol or placebo 1 h before the procedure. In addition, an NSAID (to alleviate misoprostol-induced uterine cramping) was administered in both treatment groups. The primary end-point was ease of insertion rather than pain ([@DMT022C43]).

The second RCT was conducted in 89 women who had already had on average two births and were having a repeat LNG-IUS inserted: 400 µg sublingual misoprostol or placebo was given 3 h before the procedure without co­administration of an NSAID. Again, the primary end-point was ease of insertion rather than pain ([@DMT022C23]).

In the third trial, 40 nulliparous women were randomized to receive 400 µg misoprostol or placebo administered buccally 90 min before the procedure. Administration of oral analgesia or local anaesthesia was at the discretion of the provider and was reported by treatment group ([@DMT022C17]). The primary end-point was pain measured on a VAS (0--100 mm) ([@DMT022C25]) at various time points before, during and after insertion ([@DMT022C17]).

The fourth trial was conducted in 199 women, of whom 95 were nulliparous and 104 were parous. Women received 400 µg misoprostol or placebo vaginally 3 h before the procedure. Co-administration of NSAIDs was not permitted. The primary end-point was placement failure not pain ([@DMT022C15]).

In the fifth trial, 108 nulliparous women who requested IUC were randomized to self-administer either 400 μg misoprostol or placebo vaginally or buccally 3--4 h before the insertion procedure. Use of prophylactic analgesia and local anaesthesia was permitted at the discretion of the investigator. Again, the primary end-point was ease of insertion rather than pain. However, subjects reported pain on a 0--100 VAS at the following time points: before insertion, immediately post-insertion and before clinic discharge ([@DMT022C51]).

In one of the five trials, the use of misoprostol compared with placebo was shown to significantly increase ease of insertion from the blinded investigator\'s perspective ([@DMT022C43]). However, none of the five RCTs demonstrated a significant reduction in patient-reported pain with misoprostol compared with placebo. In the most recent study ([@DMT022C51]), which evaluated pain at different time points, no significant difference between the misoprostol and placebo groups was observed for pain during the actual insertion (*P* = 0.74). However, subjects randomized to misoprostol reported significantly more pain before insertion (*P* = 0.003) and a trend towards more pain immediately post-insertion (*P* = 0.07). This is likely to be related to misoprostol-induced uterine cramping.

Furthermore, in the above studies premedication with misoprostol was associated with an increase in pre-insertion side effects compared with placebo. These side effects included nausea, cramps and, particularly with sublingual administration, shivering. These are known side effects of misoprostol; their severity is dependent on the dose and route of administration. Sublingual and buccal administrations are generally associated with increased side effects compared with vaginal administration ([@DMT022C10]; [@DMT022C29]).

The authors of four of these RCTs concluded that women should not be routinely premedicated with misoprostol before IUC insertion because the potential harms outweigh the possible benefits ([@DMT022C23]; [@DMT022C15]; [@DMT022C17]; [@DMT022C51]).

#### Study limitations {#s3a2a}

To date, several aspects of cervical priming regimens for IUC insertion and removal remain unclear: the minimal dose of misoprostol and the optimal route, and the timing of administration to achieve the necessary degree of cervical softening before placement. No trial to date has sought to establish a standard on these variables. In addition, no trial has evaluated the benefits of misoprostol specifically among cases where insertion of IUC might be expected to be more difficult, such as when there is stenosis of the internal or external cervical os or when a previous insertion attempt has failed.

The regimens used in these five RCTs were based on experience from surgical abortion ([@DMT022C45], [@DMT022C46], [@DMT022C47], [@DMT022C48]). However, markedly less dilation is needed for IUC insertion. It is therefore likely that the doses of misoprostol administered in these studies were too high, causing unnecessarily high rates of side effects (mainly pain associated with uterine cramping). It is also possible that misoprostol induces more painful uterine contractions in non-pregnant women than pregnant women in whom the myometrium is protected from prostaglandin by an increased level of progesterone.

Although three of the five RCTs were conducted exclusively in nulliparous populations ([@DMT022C43]; [@DMT022C17]; [@DMT022C51]), two studies involved mixed cohorts of multiparous and nulliparous women with conclusions drawn from the overall study populations. In the mixed cohort studies, failing to analyse subsets of nulliparous women and those who have only ever undergone Caesarean section deliveries may have led to erroneous conclusions being drawn and benefits for certain subgroups could have been missed.

The second study ([@DMT022C23]) included women who had already had on average two deliveries and nulliparous women represented only 6% of the study population. This study was conducted in a highly selected cohort of women who had previously had IUC successfully inserted.

The main limitation in four of the studies was that ease of insertion or insertion failure was the primary outcome; pain was not the primary end-point in these trials and therefore overall pain was evaluated rather than differentiating between pain associated with misoprostol-induced uterine contractions and cervical pain caused by dilation. In addition, the different time points when pain occurred were recorded in only two studies. Painful uterine cramping and other unpleasant side effects associated with misoprostol are dose-dependent. It is possible that when misoprostol was given *without* an NSAID, for example, in the study by Heikinheimo and colleagues ([@DMT022C23]), the pain experienced in the placebo group was mostly related to IUC insertion and cervical in origin, whereas the pain experienced in the misoprostol group may have been associated with uterine cramping caused by the prostaglandin.

The time taken for misoprostol to exert its effect on the cervical tissue (and on uterine contractility) may vary according to the route of administration, e.g. sublingual administration has a more rapid effect than vaginal or buccal administration ([@DMT022C3]; [@DMT022C37]; [@DMT022C52]). In the study by [@DMT022C17], misoprostol was administered buccally 90 min before the procedure. This timeframe might be sufficient to cause uterine cramping but might not be long enough to soften the cervical tissue ([@DMT022C37]). Based on studies on cervical priming prior to surgical abortion, misoprostol should be administered at least 3 h in advance if administered buccally or vaginally. This is in contrast to sublingual administration, which results in a rapid onset of action, based on pharmacokinetics in pregnant women ([@DMT022C52]).

In addition, the results of the study by [@DMT022C17] are difficult to interpret because additional oral analgesia and local anaesthesia (by various techniques) were given at the discretion of the investigator in both treatment arms but not reported in the publication, and only 40 women were evaluated.

Studies on the prophylactic use of mifepristone or spasmolytics for IUC placement have not been reported. The effect of cervical priming with mifepristone has been investigated in two RCTs conducted in other gynaecological settings; the first in 30 women undergoing surgical abortion, the second in non-pregnant premenopausal women about to undergo either cervical dilatation and diagnostic curettage or laparoscopic sterilization. In both the pregnant and non-pregnant controls, 600 mg of mifepristone given orally 48 h prior to surgery increased the mean pre-operative cervical dilation and reduced the force required to dilate the cervix ([@DMT022C22]).

#### Group consensus {#s3a2b}

A small group of women experience severe pain during IUC insertion and need special attention. Currently there is no accepted standard for prevention or treatment of these symptoms. Although there were limitations in the design and conduct of the above studies, and therefore in the conclusions that could be drawn, there is currently no clear evidence to support the routine use of misoprostol at the 400 µg dose in all women for pain control. There is no clear evidence that pain is reduced from the woman\'s perspective and potential harms may outweigh the possible benefits of the misoprostol regimens used in RCTs to date. In addition, in the absence of studies, there is no evidence to support routine use of mifepristone in the context of IUC placement.

For most nulliparous, nulligravid or parous women, IUC insertion can be performed successfully without cervical priming and with a minimum amount of discomfort ([@DMT022C6]). Whether selective use of misoprostol has a role in management of pain in certain subsets of women (e.g. nulliparous women and those in whom the insertion is non-routine/difficult) has yet to be adequately studied.

There is currently some evidence that misoprostol eases insertion from the provider\'s perspective. If misoprostol is to be used for cervical priming/ripening to improve technical ease in certain groups of women, we recommend that an NSAID (e.g. diclofenac or ibuprofen) is co-administered to manage the prostaglandin-mediated side effects (e.g. uterine cramping).

### Pre-insertion local anaesthesia {#s3a3}

The term 'local anaesthesia' has a different meaning to different providers and includes a number of formulations (e.g. gel, injections and spray) and techniques for administration (intracervical and paracervical).

Lignocaine gel: The application of local anaesthetic lignocaine gel before IUC insertion has been evaluated in three RCTs ([@DMT022C41]; [@DMT022C34]; [@DMT022C36]) (Table [I](#DMT022TB1){ref-type="table"}).

The first trial was a single-centre UK-based study, which evaluated the efficacy of 2% lignocaine gel, inactive placebo gel or 'no treatment' applied to the cervical canal for reduction in pain in 102 nulliparous or parous women ([@DMT022C41]). Intracervical application of 2% lignocaine gel resulted in a significant reduction in pain compared with no active treatment (placebo gel or no treatment; *P* \< 0.025). Using a scale of 1--7, pain scores of 1--2, 3--4 and 5--7 were reported by 34 versus 10%, 48 versus 60% and 18 versus 29% of women in the lignocaine gel versus no active treatment groups, respectively. However, the trial was associated with several limitations; assignment of treatment was not blinded to providers, which may have influenced the results (e.g. knowing that active gel was being used may have allowed the provider to proceed with greater confidence). In addition, the treatment groups were not well balanced; a higher proportion of nulliparous women were allocated to the 'no treatment' group.

The second study was a randomized, double-blind trial of 197 women treated with intracervical 2% lignocaine gel or placebo gel prior to uterine sounding and insertion of IUC ([@DMT022C34]). There was no decrease in pain in the lignocaine group compared with the placebo group. Pain (measured by 100 mm VAS) was greatest during sounding and was similar between groups (51.6 mm in the placebo group versus 55.5 mm in the lignocaine group; *P* = 0.33). No treatment effect was seen in a stratified analysis accounting for parity.

The third study was a double-blind RCT in which women received 2% lignocaine or placebo gel applied at the planned tenaculum site and into the endocervical canal 3 min before IUC insertion ([@DMT022C36]). Women rated their pain on a 10-point VAS immediately after tenaculum placement and immediately after IUC insertion. No significant difference was observed between the treatment groups at either of the time points studied for the overall cohort of 199 nulliparous and parous women, nor in the individual subgroups of nulliparous and parous women.

Injectable local anaesthesia: This involves a series of injections of a local anaesthetic into the vaginal fornices around the cervix (paracervical block) or into the cervical stroma (intracervical block). Pain reduction is achieved by blocking nerve fibres. Various techniques and provider experiences have been discussed in the literature ([@DMT022C24]; [@DMT022C32]; [@DMT022C53]; [@DMT022C5]; [@DMT022C16]; [@DMT022C20]; [@DMT022C30]; [@DMT022C27], [@DMT022C28]).

Only one RCT has evaluated the impact of injectable local anaesthesia on pain associated with insertion of IUC. This study evaluated a 1% lignocaine paracervical block compared with no local anaesthesia on patient-reported pain in 50 nulliparous and parous women undergoing IUD insertion ([@DMT022C38]). The women rated pain on a 100 mm VAS at the following time points during the procedure: speculum insertion, tenaculum placement, paracervical block administration, IUC insertion and 5 min after completion of the procedure. After adjustment for differences in BMI, no significant difference in pain was observed between the treatment groups at any of the time points studied.

In a systematic review and meta-analysis of data on the efficacy of local anaesthesia for pain control during outpatient hysteroscopy ([@DMT022C14]), intracervical and paracervical injections of a local anaesthetic significantly reduced patient-reported pain, whereas transcervical and topical application of a local anaesthetic did not. A meta-analysis showed that paracervical injections provided superior pain reduction compared with the other techniques. However, the main problem with studying local anaesthesia in transcervical procedures is the huge variation in techniques, which are often inadequately explained, and the difficulty in evaluating diverse techniques. In addition, the terms 'paracervical' and 'intracervical' are frequently used but clinicians have different understandings of what these terms mean. For example, in one study of intracervical anaesthesia that was included in the systematic review and meta-analysis, 2 ml of 1% lignocaine was injected at the tenaculum site, which would have had no effect on the internal os. In another study of intracervical anaesthesia that was included, women received 100 mg tramadol, which might be expected to be a strong confounding factor. This systematic review is therefore a good example of the difficulties encountered when trying to conduct a meaningful analysis on the comparative effectiveness of different local anaesthesia techniques. However, from a rational standpoint, in a paracervical block local anaesthetic is injected without knowing the exact location of the target nerve, and therefore a larger volume is injected compared with an intracervical block in which the inner os is targeted directly either via the cervical canal or via cervical tissue. Importantly, however, hysteroscopy is not comparable with IUC insertion (e.g. IUC insertion requires less cervical dilation) and extrapolation of data between procedures should be viewed with caution.

#### Group consensus {#s3a3a}

There is currently no clear evidence from RCTs to recommend routine prophylactic use of local anaesthesia in any form for IUC insertions. Furthermore, there is no evidence that local anaesthesia prophylaxis is needed routinely in this setting. However, complications arising from the procedure, need for dilation and insertion pain are difficult to predict. Injectable local anaesthesia should therefore be at hand for reactive administration, intracervically or paracervically.

Post-insertion pharmacological therapy {#s3b}
--------------------------------------

### NSAIDs {#s3b1}

A systematic review of RCTs concluded that NSAIDs were effective in *reactively* treating pain after IUC insertion. However, prophylactic administration of NSAIDs after the procedure seemed to provide no significant pain reduction benefit, and caused side effects including stomach upsets and sleepiness ([@DMT022C21]).

#### Group consensus {#s3b1a}

There is currently no evidence to recommend the routine prophylactic use of an NSAID immediately after IUC insertion because there is no clear evidence of benefit. However, if a woman does develop pain after the procedure, NSAIDs can be taken.

Despite a lack of conclusive supporting evidence, prophylactic use of NSAIDs after insertion of IUC is widespread, possibly because they are inexpensive, available over the counter and associated with relatively few side effects. They may also reduce anxiety through a possible placebo effect.

### Opioid analgesia {#s3b2}

In an RCT (*n* = 59) comparing meptazinol, a partial µ-opioid receptor agonist, with placebo for the relief of pain after copper IUD insertion, no significant difference was seen between treatment groups in the patients\' global assessment of their therapy. Sixty-seven per cent and 69% of patients randomized to meptazinol and placebo, respectively, assessed their pain relief treatment as 'good or excellent', indicating either a strong placebo effect or that the procedure is pain-free or well tolerated by most women ([@DMT022C19]).

#### Group consensus {#s3b2a}

There is no evidence to support the routine use of narcotics for the treatment of pain after IUC insertion, and therefore, it is not recommended. There is no clear evidence of clinical benefit, and providers should question the cause of such pain that it warrants narcotic pain relief (e.g. have complications occurred?). Use of opioids may be appropriate only in very rare cases.

Non-pharmacological pain management strategies {#s3c}
----------------------------------------------

### Pre-insertion counselling {#s3c1}

In a study evaluating the benefits of a psychological preparation interview, clear benefits in reducing patient-perceived pain at IUD insertion were reported ([@DMT022C40]). The authors suggested that psychological preparation may reduce the perception of pain by reducing uncertainty, providing information/reassurance on what to expect and increasing motivation leading to higher tolerance of discomfort.

### Management of women\'s anxiety {#s3c2}

A UK-based study of IUC insertions performed at a single centre ([@DMT022C39]) concluded that women who were more anxious and who anticipated that the procedure would be painful, even if it was not as bad as they expected at the time of the procedure, recalled 6 months later that it was a painful experience. In addition, women who choose to take oral analgesia before the procedure may be the most anxious, and higher anxiety levels may contribute to perceived pain.

#### Group consensus {#s3c2a}

Strategies aimed at reducing women\'s anxiety before and during the insertion procedure are important and may be effective in reducing pain associated with IUC insertion. The most anxious women may be those with mood disorders, a history of sexual trauma, a previous negative reaction to vaginal examination or a previous insertion that was painful and those who have heard from a peer about a painful procedure. These contributory factors have not been studied in any detail.

Data gaps and areas for further research {#s4}
========================================

Oral analgesia {#s4a}
--------------

There is a general paucity of data on the use of pre-insertion oral analgesia. Furthermore, the regimens currently used in this context have been extrapolated from gynaecological procedures, such as hysteroscopy and surgical abortion.

Cervical priming {#s4b}
----------------

There are insufficient data on the use of cervical priming for reduction of pain associated with IUC insertion in non-routine cases and in nulliparous or nulligravid women. There are also insufficient data to determine the optimal dose, route and timing of misoprostol administration. The current regimens are derived from other gynaecological procedures, such as surgical abortion and hysteroscopy, in which wider cervical dilation is needed.

Future studies of misoprostol should focus on the evaluation of pain before, during and after IUC insertion rather than on overall pain, to differentiate the possible cause of pain at different time points. A lower misoprostol dose for IUC insertions could also be explored because less cervical dilation is required in this setting compared with other gynaecological procedures. Furthermore, dose reduction has the potential to induce less pain from prostaglandin-induced uterine cramping. Evaluation of other substances, such as mifepristone or spasmolytic drugs, is also recommended.

Local anaesthesia {#s4c}
-----------------

There is a lack of studies evaluating the efficacy of different techniques for administering local anaesthesia to help reduce pain associated with IUC insertion. The available data on the use of local anaesthesia are mainly derived from studies of hysteroscopy. Studies are needed to directly compare different formulations (e.g. gel versus spray versus injectables), different administration techniques (e.g. intracervical versus paracervical) and different injectable anaesthetic drugs.

Non-pharmacological interventions {#s4d}
---------------------------------

Studies evaluating the impact of non-pharmacological interventions (e.g. pre-insertion counselling and the effect of an assistant providing reassurance and distraction during the procedure) are lacking. Data from such studies are needed to share best practices internationally.

Summary and conclusions {#s5}
=======================

Although IUC insertions can be performed in the majority of women without pharmacological interventions to reduce pain, a relevant percentage of women would benefit from such measures. After critical evaluation of the evidence, it can be concluded that no prophylactic pharmacological intervention has been adequately evaluated to support its routine use for reduction of pain during or after IUC insertion. Most regimens have been adapted from other gynaecological procedures and their effectiveness in providing pain relief in specific subsets of women has not been studied.

There is some evidence to suggest that non-pharmacological interventions might reduce pain levels. Women\'s anxiety about the procedure may contribute to higher levels of perceived pain during IUC insertion, highlighting the importance of pre-insertion counselling, and 'verbal anaesthesia' and distraction during the procedure to help minimize anxiety. Further studies focusing on non-pharmacological interventions need to be conducted and reported in the literature to disseminate best practice advice internationally.
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[^1]: CI, confidence interval; NSAID, non-steroidal anti-inflammatory drug; VAS, visual analogue scale.

[^2]: ^a^For studies in which pain was evaluated at different time points, the time points included one or more of the following: at speculum insertion, at tenaculum placement, during the actual insertion of the device, shortly after insertion of the device.

[^3]: ^b^Oxford Centre for Evidence-Based Medicine (2011) levels of evidence: Level 1, systematic review of randomized trials; Level 2, randomized trial or an observational study with dramatic effect; Level 3, non-randomized controlled cohort/follow-up study; Level 4, case-series, case--control studies or historically controlled studies; Level 5, mechanism-based reasoning.

[^4]: ^c^Study was associated with a number of limitations, e.g. assignment of treatment was not blinded to providers and the treatment groups were not well balanced with regard to parity.
